Richmond Pharmacology continually evaluates the processes we undertake and examine whether they deliver maximum value to trial sponsors while not compromising quality or patient safety.

One of the ways we do this is through the use of adaptive trial protocols which enables the safe modification of a trial’s course in accordance with pre-specified rules in the protocol. Modifications may include for example, the need to change the patient sample size, review the data collected and evaluate which groups of patients are responding.

One of the reasons why the UK is an outstanding location to deliver clinical studies is that the regulator - the MHRA - embrace and support the use of adaptive trial protocols. This allows Contract Research Organisation’s such as us the ability to operate more flexibly and to take decisions faster; ensuring that trials can reach their end points sooner and the most promising therapeutics move to the next stage more quickly.

To read the full article, click here. If you would like to learn more about the value of adaptive protocols in clinical trials please contact us

Latest news

Engaging Hearts and Hands: A Day of Volunteering at Arc Nursery

September 12, 2023
Discover how Richmond's dedicated team of volunteers is making a positive impact on young minds at Arc Nursery
Read more

Exciting Research Update: Enhancing Blinding in Clinical Trials with Auto-Injectors

September 5, 2023
We’re excited to share the findings of our recent study on the use of auto-injector systems (A-INJ) in randomized controlled trials (RCTs) by Dr Jorg Taubel, Dr Ulrike Lorch, Dr Thomas York and Vishal Aggarwal.
Read more

Events

BioJapan 2023

11-13 October 2023
BioJapan is "Asia's largest partnering event consisting of Exhibition, Seminar, and Partnering program".
View event